In 2023, the diagnostics sector saw over 430 Dx-related transactions, averaging approximately 110 deals per quarter. USA and North America generally dominated the deal space, with 68% of sellers and 61% of buyers. European engagement was lower, with 24% and 30% respectively.
Download Request
Despite concerns around the global political and economic landscape, the biopharmaceutical industry still maintains a favourable mid-to long-term outlook with a promising future for revenues.
The industry’s clinical pipeline remains robust, with a growing number of new molecular entities in development. Increasing complexity of molecules entering the clinical pipeline drives demand for experienced partners who can support clients, reduce investment risk and accelerate time to market.
For an overview of the key trends, current state of the market and the future outlook for CRO, CDMO, Packaging and Distribution service sectors, read PharmaVentures’ new report, Pharma Services Overview.
Download Request
Contract Development & Manufacturing Organisations (CDMOs) increasingly need to differentiate and establish their competitive advantage to effectively cater to the growing demand and to enhance their profitability. There is a greater demand for CDMOs offering broad-based best practice technologies, staff competencies and reliable delivery.
PharmaVentures is recognised as a leading transactions advisor and has advised on the strategic direction of over 40 facilities offering CRO/CDMO services and completed the sale of 14 operations globally.
In this white paper, we harness the knowledge from our extensive cross border transaction experience and industry research to look at the value drivers in the CDMO market that companies should keep in mind when they cultivate their strategies.
Whilst the Biosimilars market represents a massive commercial opportunity, the landscape is quite complex, with multiple dynamics at play. Competition is high, and research proves that there is a strong correlation between market entry order and market uptake.
How do companies with Biosimilars assets realise their value and stand out from the competition?
As experts in the Biosimilars space, PharmaVentures provides insight in this new white paper.
Download Request
To remain competitive and to take advantage of the latest innovations, life science companies can’t afford to ignore opportunities in South Korea.
PharmaVentures has successfully completed over 30 projects for South Korean biotechs and pharma companies over the last 5 years and is recognised as a leading western transaction advisory firm in the region.
In this white paper, we look at the significant innovative drug development that has taken place within South Korea during the last decade, and how we can use our experience in this area to help Western pharma and biotech companies meet their pipeline needs by accessing the companies at the cutting edge of our industry.
Download Request
More important than ever, but there’s still a way to go.
Just the other week, it was announced that Illumina had acquired GRAIL (subject to approval from the regulators), a company it formed in 2016 and spun out. Illumina retained a 12% stake in the business and has decided the time is now right to bring it back into the fold. History repeats itself in that the deal took place (as with most diagnostics) at a point at which the technology was in market, or at least market ready. The GRAIL, Galleri diagnostic test, is available as a CLIA waived test to detect 50 different cancers before symptoms appear. The test is yet to be FDA approved or reimbursed and currently costs just under $1000, but this milestone achievement, off the back of more than $2B in investment and a research effort that covered more than 100,000 people, was sufficient to make Illumina want to pay around $8B to reacquire the business.
Download Request